Masatoshi Matsunami1, Ivy A Rosales2, Benjamin A Adam3, Tetsu Oura1, Michael Mengel3, Rex-Neal Smith2, Hang Lee4, A Benedict Cosimi1, Robert B Colvin2, Tatsuo Kawai1. 1. Department of Surgery, Center for Transplantation Sciences, Massachusetts General Hospital, Harvard Medical School, Boston, MA. 2. Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA. 3. Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB, Canada. 4. Department of Biostatistics, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
Abstract
BACKGROUND: Renal allograft tolerance (TOL) has been successfully induced in nonhuman primates (NHPs) and humans through the induction of transient mixed chimerism. To elucidate the mechanisms of TOL, we compared local immunologic responses in renal allografts with those in T-cell-mediated rejection (TCMR) and chronic antibody-mediated rejection (CAMR) in NHPs. METHODS: Using the NanoString nCounter platform, we retrospectively studied 52 mRNAs in 256 kidney allograft samples taken from NHP kidney recipients of donor BMT. No immunosuppression was given after 1-month post-donor BMT. Recipients who achieved TOL (n = 13) survived for >1840 ± 1724 days with normal kidney function, while recipients with CAMR (n = 13) survived for 899 ± 550 days with compromised graft function, and recipients with TCMR (n = 15) achieved only short-term survival (132 ± 69 days). RESULTS: The most prominent difference between the groups was FOXP3, which was significantly higher in TOL than in CAMR and TCMR, both early (<1 y, P < 0.01) and late (≥1 y, P < 0.05) after transplant. Other mRNAs related to regulatory T cells (Treg), such as IL10, TGFB, and GATA3, were also high in TOL. In contrast, transcripts of inflammatory cytokines were higher in TCMR, while activated endothelium-associated transcripts were higher in CAMR than in TOL. The receiver operating characteristic analyses revealed that intragraft FOXP3 and CAV1 can reliably distinguish TOL from CAMR. CONCLUSIONS: High FOXP3 and other Treg-related mRNAs together with suppressed inflammatory responses and endothelial activation in renal allografts suggest that intragraft enrichment of Treg is a critical mechanism of renal allograft TOL induced by transient mixed chimerism.
BACKGROUND: Renal allograft tolerance (TOL) has been successfully induced in nonhuman primates (NHPs) and humans through the induction of transient mixed chimerism. To elucidate the mechanisms of TOL, we compared local immunologic responses in renal allografts with those in T-cell-mediated rejection (TCMR) and chronic antibody-mediated rejection (CAMR) in NHPs. METHODS: Using the NanoString nCounter platform, we retrospectively studied 52 mRNAs in 256 kidney allograft samples taken from NHP kidney recipients of donor BMT. No immunosuppression was given after 1-month post-donor BMT. Recipients who achieved TOL (n = 13) survived for >1840 ± 1724 days with normal kidney function, while recipients with CAMR (n = 13) survived for 899 ± 550 days with compromised graft function, and recipients with TCMR (n = 15) achieved only short-term survival (132 ± 69 days). RESULTS: The most prominent difference between the groups was FOXP3, which was significantly higher in TOL than in CAMR and TCMR, both early (<1 y, P < 0.01) and late (≥1 y, P < 0.05) after transplant. Other mRNAs related to regulatory T cells (Treg), such as IL10, TGFB, and GATA3, were also high in TOL. In contrast, transcripts of inflammatory cytokines were higher in TCMR, while activated endothelium-associated transcripts were higher in CAMR than in TOL. The receiver operating characteristic analyses revealed that intragraft FOXP3 and CAV1 can reliably distinguish TOL from CAMR. CONCLUSIONS: High FOXP3 and other Treg-related mRNAs together with suppressed inflammatory responses and endothelial activation in renal allografts suggest that intragraft enrichment of Treg is a critical mechanism of renal allograft TOL induced by transient mixed chimerism.
Authors: Y Yamada; T Ochiai; S Boskovic; O Nadazdin; T Oura; D Schoenfeld; K Cappetta; R-N Smith; R B Colvin; J C Madsen; D H Sachs; G Benichou; A B Cosimi; T Kawai Journal: Am J Transplant Date: 2014-11-13 Impact factor: 8.086
Authors: Kenneth A Newell; Adam Asare; Allan D Kirk; Trang D Gisler; Kasia Bourcier; Manikkam Suthanthiran; William J Burlingham; William H Marks; Ignacio Sanz; Robert I Lechler; Maria P Hernandez-Fuentes; Laurence A Turka; Vicki L Seyfert-Margolis Journal: J Clin Invest Date: 2010-05-24 Impact factor: 14.808
Authors: Y Yamada; S Boskovic; A Aoyama; T Murakami; P Putheti; R N Smith; T Ochiai; O Nadazdin; I Koyama; O Boenisch; N Najafian; M K Bhasin; R B Colvin; J C Madsen; T B Strom; D H Sachs; G Benichou; A B Cosimi; T Kawai Journal: Am J Transplant Date: 2011-11-04 Impact factor: 8.086
Authors: B-H Yang; S Hagemann; P Mamareli; U Lauer; U Hoffmann; M Beckstette; L Föhse; I Prinz; J Pezoldt; S Suerbaum; T Sparwasser; A Hamann; S Floess; J Huehn; M Lochner Journal: Mucosal Immunol Date: 2015-08-26 Impact factor: 7.313
Authors: Maria Lucia L Madariaga; Philip J Spencer; Kumaran Shanmugarajah; Kerry A Crisalli; David C Chang; James F Markmann; Nahel Elias; A Benedict Cosimi; David H Sachs; Tatsuo Kawai Journal: JCI Insight Date: 2016-06-02
Authors: Chad J Pendley; Ericka A Becker; Julie A Karl; Alex J Blasky; Roger W Wiseman; Austin L Hughes; Shelby L O'Connor; David H O'Connor Journal: Immunogenetics Date: 2008-05-27 Impact factor: 2.846
Authors: Danny Luan; Darshana M Dadhania; Ruchuang Ding; Thangamani Muthukumar; Michelle Lubetzky; John R Lee; Vijay K Sharma; Phyllis August; Franco B Mueller; Joseph E Schwartz; Manikkam Suthanthiran Journal: Transplantation Date: 2021-08-01 Impact factor: 5.385
Authors: Cecilia G Shortreed; Roger W Wiseman; Julie A Karl; Hailey E Bussan; David A Baker; Trent M Prall; Amelia K Haj; Gage K Moreno; Maria Cecilia T Penedo; David H O'Connor Journal: Immunogenetics Date: 2020-02-29 Impact factor: 2.846
Authors: Michael Mengel; Alexandre Loupy; Mark Haas; Candice Roufosse; Maarten Naesens; Enver Akalin; Marian C Clahsen-van Groningen; Jessy Dagobert; Anthony J Demetris; Jean-Paul Duong van Huyen; Juliette Gueguen; Fadi Issa; Blaise Robin; Ivy Rosales; Jan H Von der Thüsen; Alberto Sanchez-Fueyo; Rex N Smith; Kathryn Wood; Benjamin Adam; Robert B Colvin Journal: Am J Transplant Date: 2020-06-27 Impact factor: 9.369